Teva Pharmaceuticals has announced theintroduction and availability of Clopidogrel Tablets, an AB rated andbioequivalent product to Plavix Tablets (Bristol-Myers Squibb and SanofiAventis). Clopidogrel Tablets 75mg are available from Teva in 30, 90, and 500count bottles.
Mylan Pharmaceuticals receivedapproval to market Clopidogrel Tablets 75mg and 300mg. The 75mg tabletwill be supplied in bottle form and unit dose packs of 100, while the 300mgtablet will be available in unit dose packs of 30.
Dr. Reddy’s has launched ClopidogrelTablets 75mg and 300mg. The 75mg tablets are available in 30, 90, and 500 countbottles; the 300mg tablets are available in blister packs of 30-count.
Plavix, a platelet aggregationinhibitor, is indicated for:
- Acute coronary syndrome:
– For patients with non-ST-segmentelevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction(NSTEMI)] including patients who are to be managed medically and those who areto be managed with coronary revascularization, Plavix has been shown todecrease the rate of a combined endpoint of cardiovascular death, myocardialinfarction (MI), or stroke as well as the rate of a combined endpoint ofcardiovascular death, MI, stroke, or refractory ischemia.
-For patients withST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce therate of death from any cause and the rate of a combined endpoint of death,re-infarction, or stroke. The benefit for patients who undergo primary PCI isunknown.
- Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.